Trevena (NASDAQ:TRVN) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Trevena, Inc. (NASDAQ:TRVN)’s stock price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $6.99 and traded as low as $1.80. Trevena shares last traded at $1.98, with a volume of 12,859 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Trevena in a research report on Monday, October 7th. They issued a “sell” rating on the stock.

Trevena Stock Up 9.9 %

The firm’s 50-day moving average price is $4.09 and its 200 day moving average price is $6.85.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($9.25) by $9.02. The firm had revenue of $0.33 million during the quarter. Sell-side analysts predict that Trevena, Inc. will post -32.25 earnings per share for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.